FindTrial
Sign In

imexon

DRUG6 trials

Sponsors

AmpliMed Corporation, University of Rochester

Conditions

Breast CancerBurkitt's LymphomaDiffuse Large B Cell LymphomaFollicular LymphomaLymphoplasmacytic LymphomaMalignant MelanomaMantle Cell LymphomaMarginal Zone Lymphoma

Phase 1

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma
CompletedNCT00327600
AmpliMed CorporationMalignant Melanoma
Start: 2005-07-31End: 2007-12-31Updated: 2010-09-15
Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients
CompletedNCT00327249
AmpliMed CorporationMultiple Myeloma
Start: 2005-10-31End: 2008-01-31Updated: 2009-08-11
Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients
CompletedNCT00327288
AmpliMed CorporationBreast Cancer, Non-small Cell Lung Cancer, Prostate Cancer
Start: 2005-10-31End: 2008-07-31Updated: 2015-06-24
Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy
CompletedNCT00327223
AmpliMed CorporationNeoplasm Metastasis
Start: 2005-11-30End: 2006-10-31Updated: 2008-03-14
Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma
CompletedNCT00327327
AmpliMed CorporationPancreatic Adenocarcinoma
Start: 2004-02-29End: 2009-10-31Updated: 2010-09-15

Phase 2

Imexon for Relapsed Follicular and Aggressive Lymphomas
CompletedNCT01314014
University of RochesterBurkitt's Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma +4
Start: 2011-05-31End: 2014-08-31Updated: 2016-01-06

Related Papers

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma
Blood2014-07-1235 citations
Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study
Blood2013-11-15